Emergent Biosolutions (EBS) Financials

Emergent BioSolutions’ latest statements show a sharp rebound in quarterly revenue and operating cash flow, but the improvement remains uneven. Q2 2026 revenue increased to $234.3 million from $156.1 million in Q1 2026 and $140.9 million in the restated Q2 2025. Gross profit also rose to $137.2 million, producing a gross margin of approximately 58.5%, up from 53.8% in Q1 and 52.5% in Q2 2025.

However, a $191.3 million impairment charge pushed Q2 operating income to a $125.1 million loss and net income to a $180.2 million loss, or $3.49 per diluted share. The impairment was a noncash expense, but it signals continued pressure on the value or performance of certain assets. Investors should also note that several earlier periods were restated or contain unusual data, making long-term comparisons more difficult.

• Revenue momentum improved: Q2 2026 revenue increased nearly 50% sequentially and approximately 66% from the restated Q2 2025, reversing the significant decline seen between Q1 2025 and Q2 2025.
• Gross margins strengthened: Gross margin rose to about 58.5% in Q2 2026 from 53.8% in Q1 and 52.5% in Q2 2025, indicating better revenue mix, pricing, or production economics.
• Operating cash flow returned to positive territory: Cash provided by operations was $56.1 million in Q2 2026, compared with a $33.8 million use of cash in Q1. This was also an improvement from negative operating cash flow in Q3 2025.
• Debt declined from prior-year levels: Long-term debt was $581.8 million at June 30, 2026, down from $667.8 million at June 30, 2025 and $663.1 million at September 30, 2025.
• Short-term liquidity remains substantial: The company reported $666.0 million of current assets against $122.8 million of current liabilities, implying a current ratio of roughly 5.4 times.
• Cash balances are falling despite positive operating cash flow: Cash and equivalents declined to $139.7 million from $160.3 million in Q1 2026 and $267.3 million in Q2 2025. Q2 cash usage included $52.3 million of investing outflows and $24.4 million of financing outflows.
• Working capital remains inventory-heavy: Net inventory totaled $303.6 million, or about 46% of current assets. Accounts receivable also rose to $190.0 million from $121.6 million in Q1, which could support future revenue but also increases collection and inventory-management risk.
• Profitability remains highly volatile: Emergent reported net income of $6.8 million in Q1 2026 but swung to a $180.2 million loss in Q2. The company has alternated between profitable and loss-making quarters across the available periods.
• The Q2 impairment charge overwhelmed operating performance: Without the $191.3 million impairment charge, reported operating results would have been materially stronger, but the charge highlights the risk of additional asset write-downs and weakens confidence in the balance sheet’s carrying values.
• Leverage and shareholder equity remain concerns: Long-term debt of $581.8 million was more than four times quarterly revenue, while total equity fell to $341.4 million from $523.1 million a year earlier. Retained earnings also deteriorated to a deficit of $333.2 million, reflecting the company’s accumulated losses.

Overall, the statements suggest that Emergent is showing signs of operating recovery, particularly in revenue, gross margin and quarterly operating cash flow. Nevertheless, recurring losses, large impairment charges, declining cash, heavy inventory and a still-leveraged balance sheet leave the turnaround financially fragile.